고혈압 환자에서 항고혈압 약물 3종 복합제 사용 후 목표혈압 달성의 연관 요인 = Associated Factors for Target Blood Pressure Achievement after Triple Combination Therapy in Hypertensive Patients

다국어 초록 (Multilingual Abstract)

Background: The prevalence of hypertension reaches 29% in adults over 30 years of age in the Korean population; however, the control rate is merely 44%. The aim of this study was to investigate the associated factors for target blood pressure achievement after triple combination therapy in hypertensive patients.
Methods: From February 2016 to May 2018, 10 family physicians recruited 348 patients, who newly started a triple combination antihypertensive medication. Target blood pressure was defined as a systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg after 6 months of triple combination therapy.
Multivariate logistic regression analyses were performed to analyze the associated factors for target blood pressure achievement.
Results: Among the 348 study participants, 317 completed 6 months of treatment. The target achievement rate was 76.3% (242/317). The mean absolute difference and 95% confidence interval (CI) for the SBP and DBP were 10.8 mmHg (8.8 to 12.7) and 6.4 mmHg (5.1 to 7.8), respectively (P<0.05). The odds ratio (OR) for the target blood pressure achievement increased in those with college education or higher (OR, 2.69; 95% CI, 1.22-5.92), those with dyslipidemia (OR, 1.74; 95% CI, 1.01-2.99), and those who were satisfied with the medication (OR, 29.91; 95% CI, 3.70-241.92).
Conclusions: The presence of dyslipidemia and patient’s satisfaction with the medication were associated with target blood pressure achievement in our analyses. Our findings suggest the importance of patient’s factor in the control of blood pressure.

국문 초록 (Abstract)

연구배경: 고혈압의 유병률은 30세 이상 성인의 29%에 달하지만, 조절률은 44%에 불과하다. 본 연구의 목적은 고혈압 환자에서 항고혈압 약물 3종 복합제 사용 후 목표혈압달성 관련 요인을 조사하는 것이다.
방법: 2016년 2월부터 2018년 5월까지 국내 가정의학과의사 10명에게 방문한 고혈압 환자 중에서 항고혈압 약물3종 복합제를 처음 복용하기 시작한 348명의 환자를 선정하였다. 목표혈압은 항고혈압 약물 3종 복합제 투약 6개월 후수축기 혈압 140 mmHg 및 이완기 혈압 90 mmHg 미만으로정의하였다. 로지스틱 회귀분석을 수행하여 목표혈압 달성관련 요인을 분석하였다.
결과: 348명의 연구 참가자 중 317명이 6개월 동안 항고혈압 약물 3종 복합제를 복용하였으며, 목표 달성률은 76.3% (242/317)였다. SBP와 DBP의 평균 절대차와 95% 신뢰구간은 각각 -10.8 mmHg (-12.7 to -8.9), -6.4 mmHg (-7.8 to -5.1)이었다. 목표혈압 달성에 대한 오즈비는 대학교 졸업이상인 경우(OR, 2.69; 95% CI, 1.22-5.92), 이상지질혈증이동반된 경우(OR, 1.74; 95% CI, 1.01-2.99), 약물 치료에 만족한 경우(OR, 29.91; 95% CI, 3.70-241.92) 증가하였다.
결론: 본 연구에서 이상지질혈증 동반, 약물에 대한 환자만족도는 목표혈압 달성과 관련이 있었다. 본 연구 결과는혈압조절에 있어서 환자 요인이 중요하게 작용할 수 있다는것을 시사한다.

참고문헌 (Reference)

1 이동한, "지역사회 고혈압 환자에서 고혈압 조절 및 항고혈압제 복용에 관련된 요인" 대한예방의학회 36 (36): 11-297, 2003

2 성예나, "고혈압 환자의 혈압강하제 처방양상- 외래 처방전을 중심으로" 한국임상약학회 19 (19): 167-179, 2009

3 장동민, "고혈압 관리에 영향을 미치는 요인 분석:제4기 국민건강영양조사자료를 중심으로" 한국디지털정책학회 11 (11): 509-519, 2013

4 Oparil S, "Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothizide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, paralled-group study" 32 (32): 1252-1269, 2010

5 Calhoun DA, "Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial" 54 (54): 32-39, 2009

6 Daiichi Sankyo, Inc, "Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets" Daiichi Sankyo, Inc

7 Chobanian AV, "The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report" 289 (289): 2560-2572, 2003

8 Ezzati M, "Selected major risk factors and global and regional burden of disease" 360 (360): 1347-1360, 2002

9 Petrella RJ, "Prevalence, treatment, and control of hypertension in primary care: gaps, trends, and opportunities" 9 (9): 28-35, 2007

10 Rolnick SJ, "Patient characteristics associated with medication adherence" 11 (11): 54-65, 2013

11 Kalra S, "Oral insulin" 2 : 66-, 2010

12 Kereiakes DJ, "Olmesartan/amlodipine/hydrochlorothizide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study" 11 : 134-, 2012

13 Korean Society Hypertension, "Korea hypertension fact sheet 2018" 24 : 13-, 2018

14 Korea Centers for Disease Control and Prevention, "Korea health statistics 2016: Korea National Health and Nutrition Examination Survey (KNHANES VII-1)" KCDC

15 Matsumura K, "Impact of antihypertensive medication adherence on blood pressure control in hypertension: the COMFORT study" 106 (106): 909-914, 2013

16 World Health Organization, "Global status report on noncommunicable diseases 2014" World Health Organization 2014

17 Bangalore S, "Fixed-dose combinations improve medication compliance: a meta-analysis" 120 (120): 713-719, 2007

18 Webster R, "Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial" 320 (320): 566-579, 2018

19 Agyemang C, "Factors associated with hypertension awareness, treatment and control among ethnic groups in Amsterdam, the Netherlands: the SUNSET study" 20 (20): 874-881, 2006

20 Novartis Pharmaceuticals Corporation, "Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets" Novartis Pharmaceuticals Corporation

21 de la Sierra A, "Blood pressure control with angiotensin receptor blocker-based three-drug combinations. Key trials" 29 (29): 401-415, 2012

22 Kato H, "Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology" 19 (19): 465-473, 2015

23 Mazzaglia G, "Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients" 120 (120): 1598-1605, 2009

24 Dezii CM, "A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension" 9 (9): 2-6, 2009

25 James PA, "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)" 311 (311): 507-520, 2014